Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO

BlossomHill Therapeutics, Inc. (BlossomHill Therapeutics), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, has announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of US$16.00 per share. The gross proceeds to BlossomHill Therapeutics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by BlossomHill Therapeutics, are expected to be US$150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, BlossomHill Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by BlossomHill Therapeutics.

Latham & Watkins LLP is advising the underwriters in the offering with a Capital Markets team led by San Diego partner Matt Bush, with associates Omeed Valipour, Sterling Swift, and Madeline Hodges. Advice was also provided on FDA matters by Washington, D.C. partner Chad Jennings, with associate Trevor Thompson; on healthcare matters by Bay Area partner Betty Pang; on executive compensation and employee benefits matters by San Diego partner Holly Bauer, with associates Julie Voorhes and Georgianna Chan; on data privacy matters by Bay Area partner Heather Deixler, with associate Zac Alpert; on intellectual property matters by San Diego counsel Robert Yeh, with associates Arun Mohan and Andrew Wang; and on tax matters by Los Angeles partner Eric Cho.